Comprehensive Report: AG-2304

Disclaimer: This report focuses exclusively on AG-2304, an investigational drug developed by Ahn-Gook Pharmaceutical. Other products with similar designations, such as ARCT-2304 (an influenza vaccine candidate by Arcturus Therapeutics) and H1-Ag-2304 (an FDA reagent for influenza vaccine standardization), are distinct entities and are not the subject of this report.

1. Introduction and Overview of AG-2304

AG-2304 is an investigational drug candidate currently under development by Ahn-Gook Pharmaceutical Co., Ltd., a pharmaceutical company based in South Korea.[1] The compound is also referred to by the alternative names AG 2304 and AG2304 in various databases and clinical trial registries.[1] Ahn-Gook Pharmaceutical has a portfolio that includes treatments for a range of conditions, and AG-2304 represents one of its development programs in the cardiovascular and metabolic disease space.[2]

AG-2304 is classified as an antihyperlipidaemic agent and is being specifically developed for the treatment of hypercholesterolemia, with primary hypercholesterolemia being the targeted indication for its later-stage clinical trials.[3] Hypercholesterolemia, characterized by elevated levels of cholesterol in the blood, is a major risk factor for cardiovascular diseases. The development of new therapeutic options, particularly those offering improved efficacy, safety, or patient convenience, remains an area of active research.

The drug is intended for oral administration.[1] Currently, AG-2304 is in the preclinical stage of development for hypercholesterolemia in South Korea.[3] However, Ahn-Gook Pharmaceutical has plans to advance AG-2304 into human clinical trials, with a Phase 1 study in healthy volunteers (NCT06916169) and a Phase 3 study in patients with primary hypercholesterolemia (NCT06717360) slated to begin in 2025.[3]